ReviewDrug design, development and therapy2013
Current and emerging pharmacological treatments for sarcoidosis: a review.
Review in Drug design, development and therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Sarcoidosis with musculoskeletal manifestations: systematic review of non-pharmacological and pharmacological treatments.Rheumatology international · 2022Pooled it
- Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.Advances in rheumatology (London, England) · 2020Pooled it
- Managing fatigue in sarcoidosis - A systematic review of the evidence.Chronic respiratory disease · 2017Pooled it
- Exploring sarcoidosis via nailfold capillaroscopy: A window into the disease's microvascular landscape.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Article
- Latent microbial reactivation and immune dysregulation in sarcoidosis: bridging pathogenesis and precision therapeutics.Frontiers in medicine · 2025Review
- A review of sarcoidosis etiology, diagnosis and treatment.Frontiers in medicine · 2025Review
- Large Lung Consolidation: A Rare Presentation of Pulmonary Sarcoidosis.Life (Basel, Switzerland) · 2023Article
- Article
- Article
- Potential clinical utility ofJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Treatment of Sarcoidosis in US Rheumatology Practices: Data From the American College of Rheumatology's Rheumatology Informatics System for Effectiveness (RISE) Registry.Arthritis care & research · 2022Observational
- Musculoskeletal Manifestations of Sarcoidosis.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2022Review
- Effects of immunotherapies and clinical outcomes in neurosarcoidosis: a retrospective cohort study.Journal of neurology · 2021Article
- A Primer on the Clinical Aspects of Sarcoidosis for the Basic and Translational Scientist.Journal of clinical medicine · 2021Review
- Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity.Frontiers in pharmacology · 2021Review
- Etiologies of Proptosis: A review.Internal medicine review (Washington, D.C. : Online) · 2020Article
- Refractory Sarcoidosis: A Review.Therapeutics and clinical risk management · 2020Review
- Verrucous plaques on the elbows.JAAD case reports · 2019Article
- Hepatic Sarcoidosis: Natural History and Management Implications.Frontiers in medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of sarcoidosis is not standardized. Because sarcoidosis may never cause significant symptoms or organ dysfunction, treatment is not mandatory. When treatment is indicated, oral corticosteroids are usually recommended because they are highly likely to be effective in a relative short period of time. However, because sarcoidosis is often a chronic condition, long-term treatment with corticosteroids may cause significant toxicity. Therefore, corticosteroid sparing agents are often indicated in patients requiring chronic therapy. This review outlines the indications for treatment, corticosteroid treatment, and corticosteroid sparing treatments for sarcoidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.